PRP Achieves >85% Tumor Inhibition, $100M Funding and Phase 1b Trial in 2026
Propanc Biopharma’s PRP achieved over 85% tumor growth inhibition in preclinical pancreatic cancer models with no major side effects. The company obtained a $100 million funding facility, FDA Orphan Drug status and plans a Phase 1b trial in 2026 enrolling 30–40 advanced solid tumor patients in a $4.42 billion market.
1. Preclinical Efficacy
Propanc’s PRP demonstrated over 85% tumor growth inhibition in pancreatic cancer animal models, with reductions in fibrosis and resistance markers and no major side effects observed.
2. Market Opportunity
The global pancreatic cancer treatment market is estimated at $4.42 billion in 2026 and projected to reach $14.43 billion by 2034 with a 16% CAGR, driven by rising incidence and demand for more effective therapies.
3. Phase 1b Trial and Funding
A Phase 1b First-In-Human trial is scheduled for 2026, targeting 30–40 patients with advanced solid tumors, supported by a newly secured $100 million funding facility.
4. FDA Orphan Drug Status
PRP has received FDA Orphan Drug designation for pancreatic cancer, which may enable expedited review, development incentives and market exclusivity upon approval.